WO2011159359A2 - Serum-free chemically defined cell culture medium - Google Patents
Serum-free chemically defined cell culture medium Download PDFInfo
- Publication number
- WO2011159359A2 WO2011159359A2 PCT/US2011/001088 US2011001088W WO2011159359A2 WO 2011159359 A2 WO2011159359 A2 WO 2011159359A2 US 2011001088 W US2011001088 W US 2011001088W WO 2011159359 A2 WO2011159359 A2 WO 2011159359A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- serum
- cell culture
- amount
- culture medium
- chemically defined
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/825—Serotonine (5-HT); Melatonine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
Definitions
- Figure 5 provides images which compare multilineage differentiation potential of hMSCs after long term culture in a particular embodiment of the inventive serum-free medium to hMSCs cultured in conventional medium containing 10% FBS.
- a or “an” entity refers to one or more of that entity; for example, "a protein” or “a peptide” refers to one or more of those compounds or at least one compound.
- a protein or “a peptide” refers to one or more of those compounds or at least one compound.
- the terms “a” or “an”, “one or more” and “at least one” can be used interchangeably herein.
- a compound “selected from the group consisting of refers to one or more of the compounds in the list that follows, including combinations of two or more of the compounds.
- an isolated compound is a compound that has been removed from its natural milieu. As such, “isolated” does not necessarily reflect the extent to which the compound has been purified.
- An isolated compound of the present invention can be obtained from its natural source, can be produced using molecular biology techniques or can be produced by chemical synthesis.
- MSCs mesenchymal stem cells
- hMSCs human mesenchymal stem cells
- Embodiments of the base medium can further include an electron transport activator.
- the electron transport activator can comprise an amount of selenium or an amount of selenous acid; however, the invention is not so limited and other trace elements, metalloenzymes or proteins can be utilized to support electron transport.
- the amount can be in a range of about 0.0000025g/L and about 0.0000050 g/L with a particular embodiment including about 0.0000037 g/L.
- Embodiments of the base medium can further include one or more steroids.
- the steroids can include as non-limiting examples an amount of dexamethasone or an amount of hydrocortisone, or an amount of both.
- Particular embodiments can include an amount of dexamethasone in the range of about 2 ⁇ g/L and about 5.0 ⁇ g/L in combination with an amount of hydrocortisone of about 0.5mg/mL and about 1.5mg/mL.
- One non-limiting example of the base medium includes an amount of dexamethasone of about 0.000004 g/L in combination with an amount of hydrocortisone of about 0.001 g/L.
- embodiments of the base medium supplement can include the one or more cell growth factors such as: insulin which can be obtained from Sigma-Aldrich PN 16634 (CAS NO.: 1 1070-73-8), basic fibroblast growth factor human (bFGF) which can be obtained from Sigma-Aldrich PN F0291-25UG (CAS No.: 106096-93-9), Platelet-Derived Growth Factor bb (PDGF-bb) which can be obtained from Sigma-Aldrich PN P3201 , Epiderman Growth Factor (EGF) which can be obtained from Sigma-Aldrich PN E9644 (CAS NO.: 62253-63-8), and Insulin Like Growth Factor-1 (IGF-1) (CAS NO.: 7733-29-1) which can be obtained from Sigma-Aldrich PN 18779 or PN 13769.
- Embodiments of the base medium supplement can include an amount of insulin.
- Particular embodiments can have a concentration of bFGF in the serum-free medium in the range of about 5 ng/mL and about 20 ng/mL.
- a concentration of bFGF in the serum-free medium in the range of about 5 ng/mL and about 20 ng/mL.
- One non-limiting example includes an amount of bFGF of about 10 ng/mL.
- Embodiments of the base medium supplement can include an amount of PDGF-bb.
- Particular embodiments can have a concentration of PDGF-bb in the serum-free medium in the range of about 5 ng/mL and about 20 ng/mL.
- One non-limiting example includes an amount of PDGF-bb in the serum-free medium of about 10 ng/mL.
- Embodiments of the base medium supplement can include an amount of EGF.
- Particular embodiments can have a concentration of EGF in the serum-free medium in the range of about 15 ng/mL and about 25 ng/mL.
- One non-limiting example includes an amount EGF in the serum-free medium of about 20 ng/mL.
- PDGF-bb As to each of the above-described cell growth factors: PDGF-bb, bFGF, EGF, and IGF- 1 , there can be advantages to concentrations in the serum-free medium selected from the group including: about 2 ng/mL to about 4 ng/mL, about 3 ng/mL to about 5 ng/mL, about 4 ng/mL to about 6 ng/mL, about 5 ng/mL to about 7 ng/mL, about 6 ng/mL to about 8 ng/mL, about 7 ng/mL to about 9 ng/mL, about 8 ng/mL to about 10 ng/mL, about 9 ng/mL to about 1 1 ng/mL, about 10 ng/mL to about 12 ng/mL, about 1 1 ng/mL to about 13 ng/mL, about 12 ng/mL to about 14 ng/mL, about 13 ng/mL to about 15 ng/mL,
- Embodiments of the serum-free medium can further include an amount of transforming growth factor beta 1 ("TGFB 1 ") which can be obtained from Stem D Inc., Burlingame, CA PN TGF-b-005.
- the amount of TGFB 1 can be an amount sufficient to derive chondrocytes from mesenchymal stem cells cultured in the serum-free chemically defined cell culture medium above described.
- Particular embodiments of the serum-free medium can include a concentration of TGFB1 in the serum-free medium in the range of about 0.5 ng/mL and about 5 ng/mL.
- One non-limiting example includes an amount TGFB 1 having a concentration in the serum-free medium of about 1 ng/mL.
- Figure 9 provides a bar graph of total cell numbers over the type of culturing flask utilized in culturing hMSCs.
- Frozen bone marrow derived MSCs (Cellular Engineering Technologies) were thawed in accordance with the procedure of Example 1 .
- Bone marrow derived MSCs that had been passed for 6 passages in the inventive serum-free medium ("MesenGro") on uncoated Primaria T25 flasks were then seeded at 0.09x10 6 per flask on to two different kinds of flasks: BD Primaria T25 and Corning CellBIND T25.
- the inventive serum-free medium confers a variety of advantages over culturing MSCs or hMSCs in a medium supplemented with fetal bovine serum or with human autologous serum, or other serum containing medium.
- a first non-limiting use of embodiments of the inventive serum-free medium can be provision of a cell culture kit which includes a portion of or all of the components of the inventive serum-free medium whether combined or combinable in various permutations and combinations to prepare various embodiments of the serum-free medium for the purpose of ex- vivo expansion of cells, MSC, or hMSC populations.
- the invention involves numerous and varied embodiments of a serum-free medium including the best mode useful in the ex-vivo expansion and differentiation of cells, MSCs and hMSCs and treatment of disorders benefitted by administration of populations of MSCs or differentiated populations derived from such MSCs.
- the applicant(s) should be understood to claim at least: i) a serum-free cell culture medium as herein disclosed and described, ii) the related methods disclosed and described, iii) similar, equivalent, and even implicit variations of each of these devices and methods, iv) those alternative embodiments which accomplish each of the functions shown, disclosed, or described, v) those alternative designs and methods which accomplish each of the functions shown as are implicit to accomplish that which is disclosed and described, vi) each feature, component, and step shown as separate and independent inventions, vii) the applications enhanced by the various systems or components disclosed, viii) the resulting products produced by such systems or components, ix) methods and apparatuses substantially as described hereinbefore and with reference to any of the accompanying examples, x) the various combinations and permutations of each of the previous elements disclosed.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011265723A AU2011265723A1 (en) | 2010-06-17 | 2011-06-16 | Serum-free chemically defined cell culture medium |
EP11796094.8A EP2582788A4 (en) | 2010-06-17 | 2011-06-16 | Serum-free chemically defined cell culture medium |
KR1020137001012A KR20130112028A (en) | 2010-06-17 | 2011-06-16 | Serum-free chemically defined cell culture medium |
BR112012032164A BR112012032164A2 (en) | 2010-06-17 | 2011-06-16 | serum-free chemically defined cell culture medium |
MX2012014232A MX2012014232A (en) | 2010-06-17 | 2011-06-16 | Serum-free chemically defined cell culture medium. |
CN2011800397716A CN103068969A (en) | 2010-06-17 | 2011-06-16 | Serum-free chemically defined cell culture medium |
US13/703,296 US20130089928A1 (en) | 2010-06-17 | 2011-06-16 | Serum-Free Chemically Defined Cell Culture Medium |
JP2013515322A JP2013529917A (en) | 2010-06-17 | 2011-06-16 | Chemically defined serum-free cell culture medium |
US15/166,965 US10287550B2 (en) | 2010-06-17 | 2016-05-27 | Serum-free chemically defined cell culture medium |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39784710P | 2010-06-17 | 2010-06-17 | |
US61/397,847 | 2010-06-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/703,296 A-371-Of-International US20130089928A1 (en) | 2010-06-17 | 2011-06-16 | Serum-Free Chemically Defined Cell Culture Medium |
US15/166,965 Continuation US10287550B2 (en) | 2010-06-17 | 2016-05-27 | Serum-free chemically defined cell culture medium |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011159359A2 true WO2011159359A2 (en) | 2011-12-22 |
WO2011159359A3 WO2011159359A3 (en) | 2012-02-23 |
WO2011159359A4 WO2011159359A4 (en) | 2012-04-19 |
Family
ID=45348785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/001088 WO2011159359A2 (en) | 2010-06-17 | 2011-06-16 | Serum-free chemically defined cell culture medium |
Country Status (9)
Country | Link |
---|---|
US (2) | US20130089928A1 (en) |
EP (1) | EP2582788A4 (en) |
JP (1) | JP2013529917A (en) |
KR (1) | KR20130112028A (en) |
CN (1) | CN103068969A (en) |
AU (1) | AU2011265723A1 (en) |
BR (1) | BR112012032164A2 (en) |
MX (1) | MX2012014232A (en) |
WO (1) | WO2011159359A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103060264A (en) * | 2012-12-20 | 2013-04-24 | 上海市第十人民医院 | Stem cell culture medium and application thereof and stem cell cultivation method |
CN103255103A (en) * | 2013-04-17 | 2013-08-21 | 广州爱菲科生物科技有限公司 | Serum-free adipose tissue-derived mesenchymal stem cell culture medium |
WO2013165252A1 (en) * | 2012-05-03 | 2013-11-07 | Erasmus University Medical Center Rotterdam | Culturing of mesenchymal stem cells |
WO2015009146A1 (en) * | 2013-07-15 | 2015-01-22 | Erasmus University Medical Center Rotterdam | Method and culture medium for in vitro culturing of stem cells |
JP2015526067A (en) * | 2012-06-26 | 2015-09-10 | ケー−ステムセル カンパニー リミテッドK−Stemcell Co., Ltd. | Method for producing high-concentration stem cells |
EP2772534A4 (en) * | 2011-10-27 | 2016-02-17 | Nat Univ Corp Tokyo Med & Dent | Technique for isolating/culturing colorectal epithelial stem cell, and technique for transplanting colorectal epithelium employing said technique |
KR20160018668A (en) * | 2013-06-12 | 2016-02-17 | 가부시키가이샤 시세이도 | Serum-free medium containing pdgf for ds cells |
WO2016139340A1 (en) * | 2015-03-04 | 2016-09-09 | Mesoblast International Sàrl | Cell culture method for mesenchymal stem cells |
WO2016170281A1 (en) | 2015-04-23 | 2016-10-27 | Etablissement Francais Du Sang | Method for preserving cells, tissues or organs in hypothermia |
CN106222136A (en) * | 2016-08-08 | 2016-12-14 | 安徽惠恩生物科技股份有限公司 | A kind of culture medium for fat stem cell |
WO2020045836A1 (en) * | 2018-08-29 | 2020-03-05 | 주식회사 스템모어 | Composition for culturing dermal papilla cell and dermal papilla cell-culturing method using same |
CN112322580A (en) * | 2017-04-28 | 2021-02-05 | 北京赛斯达生物技术有限公司 | Application of serum-free medium for mesenchymal stem cells |
CN112725259A (en) * | 2021-01-07 | 2021-04-30 | 福州市皮肤病防治院 | Induction medium and induction method for differentiation of stem cells into sweat gland-like cells |
WO2023044443A1 (en) * | 2021-09-16 | 2023-03-23 | Life Technologies Corporation | Cell expansion methods and compositions for use therein |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5993113B2 (en) * | 2011-01-31 | 2016-09-14 | 株式会社 バイオミメティクスシンパシーズ | Human adipose tissue-derived mesenchymal stem cells for the treatment of Alzheimer's disease |
KR102219743B1 (en) * | 2013-11-01 | 2021-02-23 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | Novel chondrocyte induction method |
CN104630138B (en) * | 2013-11-06 | 2017-11-14 | 陕西瑞盛生物科技有限公司 | A kind of serum-free cultured chondrocytes liquid |
CN103805562B (en) * | 2014-01-13 | 2015-08-05 | 章毅 | Cultivate the serum free medium of placenta mesenchyma stem cell |
US10435464B1 (en) * | 2014-09-05 | 2019-10-08 | Coherus Biosciences, Inc. | Methods for making recombinant proteins |
WO2016179243A1 (en) * | 2015-05-05 | 2016-11-10 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Reversion of primed pluripotent stem cells to naive pluripotent stem cells |
CN104830753B (en) * | 2015-05-20 | 2018-07-10 | 广州赛莱拉干细胞科技股份有限公司 | A kind of induced multi-potent stem cell culture medium, application and cultural method |
WO2016187820A1 (en) * | 2015-05-26 | 2016-12-01 | 中国科学院广州生物医药与健康研究院 | Human primary cell culture medium and use thereof |
CN105779385A (en) * | 2016-03-31 | 2016-07-20 | 谷超 | Mesenchymal stem cell culture kit |
US11111480B2 (en) | 2016-04-29 | 2021-09-07 | Hope Biosctences, Llc | Culture media for multipotent stem cells |
US10894947B1 (en) | 2016-04-29 | 2021-01-19 | Hope Biosciences, Llc | Method for generating protein rich conditioned medium |
US10988731B2 (en) | 2016-04-29 | 2021-04-27 | Hope Biosciences, Llc | Formulation for storage, transportation, and delivery of protein rich conditioned medium |
US10959425B2 (en) | 2016-04-29 | 2021-03-30 | Hope Biosciences, Llc | Method of banking stem cells |
CN105769740B (en) * | 2016-05-11 | 2019-03-19 | 紫程瑞生会(北京)生物技术发展有限公司 | A kind of preparation method and products thereof of the biological beauty raw material in human stem cell source |
CN106244527B (en) * | 2016-08-29 | 2019-10-08 | 广东依浦赛生物科技有限公司 | Source of people iPS stem cell in vitro directed differentiation is the kit and method of cardiac muscle cell |
CN106916784A (en) * | 2017-05-04 | 2017-07-04 | 刘力伟 | A kind of serum free medium and its application for human mesenchymal stem cell |
CN107119011A (en) * | 2017-05-04 | 2017-09-01 | 刘力伟 | A kind of culture medium and its amplification method for being used to expand human mesenchymal stem cell |
USD875967S1 (en) | 2017-07-14 | 2020-02-18 | Hope Biosciences, Llc | Container for storing biological material |
USD848022S1 (en) | 2017-07-14 | 2019-05-07 | Hope Biosciences, Llc | Container for storing biological material |
CN107345216B (en) * | 2017-07-28 | 2020-11-06 | 暨南大学 | Adipose-derived stem cell culture medium and application thereof |
KR20190060716A (en) * | 2017-11-24 | 2019-06-03 | 주식회사 차바이오랩 | Serum-free medium composition |
CN109022356A (en) * | 2018-08-30 | 2018-12-18 | 丰泽康生物医药(深圳)有限公司 | A kind of serum free medium improving mesenchymal stem cells into chondrocytes differentiation |
CN109554351A (en) * | 2018-12-12 | 2019-04-02 | 山西医科大学 | The application of Rspo1 inducing bone mesenchymal stem cell Cardiocytes differentiation |
CN110016461A (en) * | 2019-01-15 | 2019-07-16 | 深圳市第二人民医院 | A kind of cartilage cell's amplification in vitro method |
CN111808799B (en) * | 2020-08-28 | 2021-07-13 | 河南昆仑精准医疗科技有限公司 | Multifunctional stem cell culture method and culture medium used by same |
CN113337457A (en) * | 2021-06-01 | 2021-09-03 | 澳门大学 | Method for serum-free regulation of cell state of stem cells and application of regulator |
CN113512533A (en) * | 2021-07-30 | 2021-10-19 | 创芯国际生物科技(广州)有限公司 | Preparation method and application of high-precision tissue chip |
US20230257714A1 (en) * | 2022-02-07 | 2023-08-17 | Smartcella Solutions Ab | Methods and compositions for generating human induced mesenchymal stem cells |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5908782A (en) | 1995-06-05 | 1999-06-01 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
US7015037B1 (en) * | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
EP1379268A1 (en) * | 2001-02-23 | 2004-01-14 | Genetics Institute, LLC | Chondrogenic potential of human bone marrow-derived cd105?+ cells by bmp |
EP1511838A4 (en) * | 2002-06-07 | 2007-01-10 | Es Cell Int Pte Ltd | Methods of regulating differentiation in stem cells |
US7723106B2 (en) | 2004-07-29 | 2010-05-25 | Food Industry Research & Development Institute | Stroma-free, serum-free, and chemically defined medium and method for ex vivo mononuclear cell expansion using the same |
US7955846B2 (en) * | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
CA2613812A1 (en) | 2005-01-31 | 2006-08-10 | Es Cell International Pte Ltd. | Directed differentiation of embryonic stem cells and uses thereof |
KR101107835B1 (en) * | 2006-01-13 | 2012-02-09 | 가부시키가이샤 투셀 | Culture Medium Additive for Use in Serum-Free Culturing of Animal Cell, Kit, and Use Thereof |
US20070287176A1 (en) * | 2006-06-13 | 2007-12-13 | Alireza Rezania | Chorionic villus derived cells |
WO2008087257A1 (en) * | 2007-01-18 | 2008-07-24 | Suomen Punainen Risti, Veripalvelu | Novel methods and reagents directed to production of cells |
JP5646990B2 (en) * | 2007-04-23 | 2014-12-24 | ストワーズ インスティテュート フォー メディカル リサーチ | Methods and compositions for stem cell self-renewal |
US8716018B2 (en) * | 2008-03-17 | 2014-05-06 | Agency For Science, Technology And Research | Microcarriers for stem cell culture |
DK2329012T3 (en) * | 2008-08-20 | 2020-08-24 | Celularity Inc | Treatment of stroke using isolated placental cells |
-
2011
- 2011-06-16 EP EP11796094.8A patent/EP2582788A4/en not_active Withdrawn
- 2011-06-16 CN CN2011800397716A patent/CN103068969A/en active Pending
- 2011-06-16 AU AU2011265723A patent/AU2011265723A1/en not_active Abandoned
- 2011-06-16 MX MX2012014232A patent/MX2012014232A/en not_active Application Discontinuation
- 2011-06-16 KR KR1020137001012A patent/KR20130112028A/en not_active Application Discontinuation
- 2011-06-16 US US13/703,296 patent/US20130089928A1/en not_active Abandoned
- 2011-06-16 BR BR112012032164A patent/BR112012032164A2/en not_active IP Right Cessation
- 2011-06-16 JP JP2013515322A patent/JP2013529917A/en not_active Withdrawn
- 2011-06-16 WO PCT/US2011/001088 patent/WO2011159359A2/en active Application Filing
-
2016
- 2016-05-27 US US15/166,965 patent/US10287550B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP2582788A4 |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2772534A4 (en) * | 2011-10-27 | 2016-02-17 | Nat Univ Corp Tokyo Med & Dent | Technique for isolating/culturing colorectal epithelial stem cell, and technique for transplanting colorectal epithelium employing said technique |
WO2013165252A1 (en) * | 2012-05-03 | 2013-11-07 | Erasmus University Medical Center Rotterdam | Culturing of mesenchymal stem cells |
JP2015526067A (en) * | 2012-06-26 | 2015-09-10 | ケー−ステムセル カンパニー リミテッドK−Stemcell Co., Ltd. | Method for producing high-concentration stem cells |
CN103060264B (en) * | 2012-12-20 | 2015-01-21 | 上海市第十人民医院 | Stem cell culture medium and application thereof and stem cell cultivation method |
CN103060264A (en) * | 2012-12-20 | 2013-04-24 | 上海市第十人民医院 | Stem cell culture medium and application thereof and stem cell cultivation method |
CN103255103A (en) * | 2013-04-17 | 2013-08-21 | 广州爱菲科生物科技有限公司 | Serum-free adipose tissue-derived mesenchymal stem cell culture medium |
CN103255103B (en) * | 2013-04-17 | 2015-01-14 | 冯文峰 | Serum-free adipose tissue-derived mesenchymal stem cell culture medium |
KR102347062B1 (en) | 2013-06-12 | 2022-01-03 | 가부시키가이샤 시세이도 | Serum-free medium containing pdgf for ds cells |
EP3009503A4 (en) * | 2013-06-12 | 2016-10-26 | Shiseido Co Ltd | Serum-free medium containing pdgf for ds cells |
KR20160018668A (en) * | 2013-06-12 | 2016-02-17 | 가부시키가이샤 시세이도 | Serum-free medium containing pdgf for ds cells |
TWI666320B (en) * | 2013-06-12 | 2019-07-21 | 日商資生堂股份有限公司 | Serum-free medium for platelet-derived growth factor (PDGF) -containing DS cells |
US11427807B2 (en) | 2013-06-12 | 2022-08-30 | Shiseido Company, Ltd. | Serum-free medium containing PDGF for DS cells |
WO2015009146A1 (en) * | 2013-07-15 | 2015-01-22 | Erasmus University Medical Center Rotterdam | Method and culture medium for in vitro culturing of stem cells |
WO2016139340A1 (en) * | 2015-03-04 | 2016-09-09 | Mesoblast International Sàrl | Cell culture method for mesenchymal stem cells |
US11685899B2 (en) | 2015-03-04 | 2023-06-27 | Mesoblast International Sarl | Cell culture method for mesenchymal stem cells |
EP4008775A1 (en) * | 2015-03-04 | 2022-06-08 | Mesoblast International Sàrl | Cell culture method for mesenchymal stem cells |
AU2016227607B2 (en) * | 2015-03-04 | 2021-09-30 | Mesoblast International Sarl | Cell culture method for mesenchymal stem cells |
WO2016170281A1 (en) | 2015-04-23 | 2016-10-27 | Etablissement Francais Du Sang | Method for preserving cells, tissues or organs in hypothermia |
CN106222136A (en) * | 2016-08-08 | 2016-12-14 | 安徽惠恩生物科技股份有限公司 | A kind of culture medium for fat stem cell |
CN112322580B (en) * | 2017-04-28 | 2022-03-22 | 北京赛斯达生物技术有限公司 | Application of serum-free medium for mesenchymal stem cells |
CN112322580A (en) * | 2017-04-28 | 2021-02-05 | 北京赛斯达生物技术有限公司 | Application of serum-free medium for mesenchymal stem cells |
WO2020045836A1 (en) * | 2018-08-29 | 2020-03-05 | 주식회사 스템모어 | Composition for culturing dermal papilla cell and dermal papilla cell-culturing method using same |
CN112725259A (en) * | 2021-01-07 | 2021-04-30 | 福州市皮肤病防治院 | Induction medium and induction method for differentiation of stem cells into sweat gland-like cells |
CN112725259B (en) * | 2021-01-07 | 2023-08-29 | 福州市皮肤病防治院 | Induction medium and induction method for differentiation of stem cells into sweat gland-like cells |
WO2023044443A1 (en) * | 2021-09-16 | 2023-03-23 | Life Technologies Corporation | Cell expansion methods and compositions for use therein |
Also Published As
Publication number | Publication date |
---|---|
EP2582788A4 (en) | 2014-03-19 |
WO2011159359A4 (en) | 2012-04-19 |
US20160281060A1 (en) | 2016-09-29 |
EP2582788A2 (en) | 2013-04-24 |
CN103068969A (en) | 2013-04-24 |
WO2011159359A3 (en) | 2012-02-23 |
MX2012014232A (en) | 2013-03-21 |
KR20130112028A (en) | 2013-10-11 |
BR112012032164A2 (en) | 2017-11-28 |
JP2013529917A (en) | 2013-07-25 |
US20130089928A1 (en) | 2013-04-11 |
US10287550B2 (en) | 2019-05-14 |
AU2011265723A1 (en) | 2013-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10287550B2 (en) | Serum-free chemically defined cell culture medium | |
AU2007210580B2 (en) | A method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses | |
JP4532493B2 (en) | Cell culture media | |
AU2012346645B2 (en) | Culture-medium composition for rejuvenating stem cells | |
US20150118748A1 (en) | High-concentration stem cell production method | |
EP2837682B1 (en) | Use of aspirin in composition for preventing stem cell disruption and aggregation | |
US20070282456A1 (en) | Compositions and Methods for Myogenesis of Fat-Derived Stem Cells Expressing Telomerase and Myocardin | |
CN112608894A (en) | Mesenchymal stem cell culture medium | |
WO2019023793A1 (en) | Generation of oligodendrogenic neural progenitor cells | |
US11859206B2 (en) | Generation of oligodendrogenic neural progenitor cells | |
US20160186132A1 (en) | Process for producing multipotent stem cells and progenitors | |
KR102296986B1 (en) | Development of a chemically defined stem cell culture media to overcome the harmfulness of fetal bovine serum | |
EP2746386A1 (en) | Materials and methods for cell culture | |
Ernst et al. | An improved, standardised protocol for the isolation, enrichment and targeted neural differentiation of Nestin+ progenitors from adult human dermis | |
TW201418465A (en) | Culture medium for human mesenchymal stem cells | |
Loo et al. | Primary and multipassage culture of human fetal kidney epithelial progenitor cells | |
AU2012227337B2 (en) | A method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses | |
RU2575106C1 (en) | Culture medium for rejuvenation of stem cells | |
JP2023035731A (en) | Hematopoietic stem cell culture composition | |
CN116478914A (en) | Serum-free cell culture system and cell digestion stopping solution thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180039771.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11796094 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3813/KOLNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/014232 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13703296 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2013515322 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011265723 Country of ref document: AU Date of ref document: 20110616 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20137001012 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011796094 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112012032164 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121217 |